{"success":true,"data":{"pressRelease":{"id":"138896","rtpr_id":"nGNX238Mc8-20260909","ticker":"KNE","exchange":"","all_tickers":["KNE"],"title":"Kane Biotech to Host Commercial Update Webcast on September 16","author":"Globe Newswire","published_at":"2026-09-09T11:05:00.115Z","article_body":"WINNIPEG, Manitoba, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc.\n(TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”), a\nbiotechnology company commercializing and developing technologies and products\nthat address microbial biofilms, today announced that it will host a virtual\nCommercial Update on Wednesday, September 16, 2026, at 11:00 a.m. Eastern\nTime.\n                   \nThe one-hour webcast will provide shareholders, prospective investors and\nother stakeholders with an update on Kane’s focus on building a clinically\ncredible and commercially disciplined wound-care business, including the\nCompany’s strategy to convert revyve(®) into meaningful, recurring revenue\nthrough sustained clinical adoption, productive commercial channels and\nrepeatable product sales.\n\nThe details of the Webcast are as follows:\n\nDate: Wednesday, September 16, 2026\nTime: 11:00 a.m. Eastern Time\nDuration: Approximately 60 minutes, including a question-and-answer session\nFormat: Virtual presentation followed by a question-and-answer session\nRegistration: Link to Registration Site\n(https://events.teams.microsoft.com/event/8d79a678-bb16-4718-9d00-2498bc681cb0@f55d812b-80ae-4d83-b8ee-725eba03df24?source=copyLinkLegacyShareLinkDialog)\n\nInvestors, shareholders and other stakeholders are encouraged to register in\nadvance to participate in the live webcast and Q&A session. A replay of the\nwebcast will be made available at www.kanebiotech.com following the event.\n\nU.S. FDA 510(k) cleared and Health Canada approved revyve Antimicrobial Wound\nGel and revyve Antimicrobial Wound Gel Spray\n\nMr. Philip Renaud, Chair of Kane’s Board of Directors, will participate in\nthe presentation.\n\nDr. John C. Lantis, Site Chief of Surgery at Mount Sinai West Hospital and\nProfessor of Surgery at the Icahn School of Medicine at Mount Sinai, will also\nparticipate in the presentation. Dr. Lantis is an experienced vascular surgeon\nand wound-care investigator who has served as principal investigator on more\nthan 70 multicentre and single-centre chronic-wound and vascular-surgery\ntrials. His presentation will provide an expert clinical perspective on\nchronic wounds, wound biofilms and the practical requirements for bringing new\nwound-care technologies into clinical use, including his experience with\nrevyve Antimicrobial Wound Spray in venous leg ulcers.\n\nDr. Robert Huizinga, Interim Chief Executive Officer of Kane Biotech, will\npresent an operational and commercial update. The presentation will address\nthe work undertaken to strengthen Kane’s commercial foundation, advance its\nclinical evidence strategy, expand routes to market and focus the Company on\nconverting commercial access into repeatable product adoption and revenue.\n\n“Over the past year, Kane has changed how it approaches governance, evidence\ngeneration and commercialization,” said Philip Renaud, Chair of the Board.\n“This webcast gives us an opportunity to speak directly to shareholders and\nother stakeholders about that work, put the Company’s progress into clear\nclinical and commercial context, and outline the execution priorities that\nwill guide Kane’s next phase.”\n\nKane’s revyve portfolio currently includes U.S. FDA 510(k) cleared revyve\nAntimicrobial Wound Gel, revyve Antimicrobial Wound Gel Spray and revyve\nAntimicrobial Skin and Wound Cleanser. The wound gel and wound gel spray are\nalso approved by Health Canada. Kane is ISO 13485:2016 certified under the\nMedical Device Single Audit Program.\n\n“Product clearance and scientific evidence are essential, but they are not\nthe same as commercial success,” said Dr. Huizinga. “Our priority is to\ntranslate Kane’s biofilm expertise and the revyve platform into sustained\nclinical adoption, productive commercial channels and demonstrable revenue\ntraction. We intend to discuss both the progress made and the work that\nremains.”\n\nAbout Kane Biotech Inc. (TSX-V:KNE)\n\nKane Biotech is commercializing and developing novel wound care treatments\nthat disrupt biofilms and transform healing outcomes. Biofilms are one of the\nmain contributors to antibiotic resistance in wounds, resulting in serious\nclinical outcomes and significant cost. revyve addresses both biofilms and\nwound bacteria. revyve Antimicrobial Wound Gel, revyve Antimicrobial Wound Gel\nSpray and revyve Antimicrobial Skin and Wound Cleanser are all U.S. FDA 510(k)\ncleared. revyve Antimicrobial Wound Gel and revyve Antimicrobial Wound Gel\nSpray are also Health Canada approved. To learn more, visit revyvegel.com\n(http://revyvegel.com) or revyvegel.ca (http://revyvegel.ca).\n\nJoin Kane’s Distribution List & Social Media:\n\nTo stay informed on the latest developments, sign up for the Company’s email\ndistribution list here (https://ir.kanebiotech.com/email-alerts).\n\nFollow Kane\n\nWebsite: kanebiotech.com (https://kanebiotech.com/)\n\nLinkedIn: https://www.linkedin.com/company/kanebiotech/\n\nPresentation: Disrupting Biofilms to Save Limbs and Transform Wound Care\n(https://kanebiotech.com/site-files/2026/05/Kane-Investor-Deck-May-2026.pdf)\n\n For more information:                               \n                                                     \n Dr. Robert Huizinga        Ray Dupuis               \n Interim CEO                Chief Financial Officer  \n Kane Biotech Inc.          Kane Biotech Inc.        \n rhuizinga@kanebiotech.com  rdupuis@kanebiotech.com  \n (780) 970-1100             (204) 298-2200           \n                                                     \n\nNeither the TSX Venture Exchange nor its Regulation Services Provider (as that\nterm is defined in policies of the TSX Venture Exchange) accepts\nresponsibility for the adequacy or accuracy of this release.\n\nCaution Regarding Forward-Looking Information\n\nThis press release contains certain statements regarding Kane Biotech Inc.\nthat constitute forward-looking information under applicable\nsecurities law. These statements reflect management’s current beliefs and\nare based on information currently available to management. Certain material\nfactors or assumptions are applied in making forward-looking statements, and\nactual results may differ materially from those expressed or implied in such\nstatements. These risks and uncertainties include, but are not limited to,\nrisks relating to the Company’s: (a) financial condition, including lack of\nsignificant revenues to date and reliance on equity and other financing; (b)\nbusiness, including its early stage of development, government regulation,\nmarket acceptance for its products, rapid technological change and dependence\non key personnel; (c) intellectual property including the ability of the\nCompany to protect its intellectual property and dependence on its strategic\npartners; and (d) capital structure, including its lack of dividends on its\ncommon shares, volatility of the market price of its common shares and public\ncompany costs. Further information about these and other risks and\nuncertainties can be found in the disclosure documents filed by the Company\nwith applicable securities regulatory authorities, available\nat www.sedarplus.ca. The Company cautions that the foregoing list of factors\nthat may affect future results is not exhaustive.\n\nA photo accompanying this announcement is available at\nhttps://www.globenewswire.com/NewsRoom/AttachmentNg/30f95b0d-a64d-4c49-9c56-daf2a8e2d906\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/a2ad1d52-1d5a-425c-93de-45cc52c3784b)\nU.S. FDA 510(k) cleared and Health Canada approved revyve Antimicrobial Wound\nGel and revyve Antimicrobial Wound Gel Spray \n(https://www.globenewswire.com/NewsRoom/AttachmentNg/30f95b0d-a64d-4c49-9c56-daf2a8e2d906/en)\nU.S. FDA 510(k) cleared and Health Canada approved revyve Antimicrobial Wound\nGel and revyve Antimicrobial Wound Gel Spray\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX238Mc8-20260909","title":"Kane Biotech to Host Commercial Update Webcast on September 16","author":"Globe Newswire","ticker":"KNE","created":"2026-09-09T11:05:00.115Z","tickers":["KNE"],"exchange":"","article_body":"WINNIPEG, Manitoba, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc.\n(TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”), a\nbiotechnology company commercializing and developing technologies and products\nthat address microbial biofilms, today announced that it will host a virtual\nCommercial Update on Wednesday, September 16, 2026, at 11:00 a.m. Eastern\nTime.\n                   \nThe one-hour webcast will provide shareholders, prospective investors and\nother stakeholders with an update on Kane’s focus on building a clinically\ncredible and commercially disciplined wound-care business, including the\nCompany’s strategy to convert revyve(®) into meaningful, recurring revenue\nthrough sustained clinical adoption, productive commercial channels and\nrepeatable product sales.\n\nThe details of the Webcast are as follows:\n\nDate: Wednesday, September 16, 2026\nTime: 11:00 a.m. Eastern Time\nDuration: Approximately 60 minutes, including a question-and-answer session\nFormat: Virtual presentation followed by a question-and-answer session\nRegistration: Link to Registration Site\n(https://events.teams.microsoft.com/event/8d79a678-bb16-4718-9d00-2498bc681cb0@f55d812b-80ae-4d83-b8ee-725eba03df24?source=copyLinkLegacyShareLinkDialog)\n\nInvestors, shareholders and other stakeholders are encouraged to register in\nadvance to participate in the live webcast and Q&A session. A replay of the\nwebcast will be made available at www.kanebiotech.com following the event.\n\nU.S. FDA 510(k) cleared and Health Canada approved revyve Antimicrobial Wound\nGel and revyve Antimicrobial Wound Gel Spray\n\nMr. Philip Renaud, Chair of Kane’s Board of Directors, will participate in\nthe presentation.\n\nDr. John C. Lantis, Site Chief of Surgery at Mount Sinai West Hospital and\nProfessor of Surgery at the Icahn School of Medicine at Mount Sinai, will also\nparticipate in the presentation. Dr. Lantis is an experienced vascular surgeon\nand wound-care investigator who has served as principal investigator on more\nthan 70 multicentre and single-centre chronic-wound and vascular-surgery\ntrials. His presentation will provide an expert clinical perspective on\nchronic wounds, wound biofilms and the practical requirements for bringing new\nwound-care technologies into clinical use, including his experience with\nrevyve Antimicrobial Wound Spray in venous leg ulcers.\n\nDr. Robert Huizinga, Interim Chief Executive Officer of Kane Biotech, will\npresent an operational and commercial update. The presentation will address\nthe work undertaken to strengthen Kane’s commercial foundation, advance its\nclinical evidence strategy, expand routes to market and focus the Company on\nconverting commercial access into repeatable product adoption and revenue.\n\n“Over the past year, Kane has changed how it approaches governance, evidence\ngeneration and commercialization,” said Philip Renaud, Chair of the Board.\n“This webcast gives us an opportunity to speak directly to shareholders and\nother stakeholders about that work, put the Company’s progress into clear\nclinical and commercial context, and outline the execution priorities that\nwill guide Kane’s next phase.”\n\nKane’s revyve portfolio currently includes U.S. FDA 510(k) cleared revyve\nAntimicrobial Wound Gel, revyve Antimicrobial Wound Gel Spray and revyve\nAntimicrobial Skin and Wound Cleanser. The wound gel and wound gel spray are\nalso approved by Health Canada. Kane is ISO 13485:2016 certified under the\nMedical Device Single Audit Program.\n\n“Product clearance and scientific evidence are essential, but they are not\nthe same as commercial success,” said Dr. Huizinga. “Our priority is to\ntranslate Kane’s biofilm expertise and the revyve platform into sustained\nclinical adoption, productive commercial channels and demonstrable revenue\ntraction. We intend to discuss both the progress made and the work that\nremains.”\n\nAbout Kane Biotech Inc. (TSX-V:KNE)\n\nKane Biotech is commercializing and developing novel wound care treatments\nthat disrupt biofilms and transform healing outcomes. Biofilms are one of the\nmain contributors to antibiotic resistance in wounds, resulting in serious\nclinical outcomes and significant cost. revyve addresses both biofilms and\nwound bacteria. revyve Antimicrobial Wound Gel, revyve Antimicrobial Wound Gel\nSpray and revyve Antimicrobial Skin and Wound Cleanser are all U.S. FDA 510(k)\ncleared. revyve Antimicrobial Wound Gel and revyve Antimicrobial Wound Gel\nSpray are also Health Canada approved. To learn more, visit revyvegel.com\n(http://revyvegel.com) or revyvegel.ca (http://revyvegel.ca).\n\nJoin Kane’s Distribution List & Social Media:\n\nTo stay informed on the latest developments, sign up for the Company’s email\ndistribution list here (https://ir.kanebiotech.com/email-alerts).\n\nFollow Kane\n\nWebsite: kanebiotech.com (https://kanebiotech.com/)\n\nLinkedIn: https://www.linkedin.com/company/kanebiotech/\n\nPresentation: Disrupting Biofilms to Save Limbs and Transform Wound Care\n(https://kanebiotech.com/site-files/2026/05/Kane-Investor-Deck-May-2026.pdf)\n\n For more information:                               \n                                                     \n Dr. Robert Huizinga        Ray Dupuis               \n Interim CEO                Chief Financial Officer  \n Kane Biotech Inc.          Kane Biotech Inc.        \n rhuizinga@kanebiotech.com  rdupuis@kanebiotech.com  \n (780) 970-1100             (204) 298-2200           \n                                                     \n\nNeither the TSX Venture Exchange nor its Regulation Services Provider (as that\nterm is defined in policies of the TSX Venture Exchange) accepts\nresponsibility for the adequacy or accuracy of this release.\n\nCaution Regarding Forward-Looking Information\n\nThis press release contains certain statements regarding Kane Biotech Inc.\nthat constitute forward-looking information under applicable\nsecurities law. These statements reflect management’s current beliefs and\nare based on information currently available to management. Certain material\nfactors or assumptions are applied in making forward-looking statements, and\nactual results may differ materially from those expressed or implied in such\nstatements. These risks and uncertainties include, but are not limited to,\nrisks relating to the Company’s: (a) financial condition, including lack of\nsignificant revenues to date and reliance on equity and other financing; (b)\nbusiness, including its early stage of development, government regulation,\nmarket acceptance for its products, rapid technological change and dependence\non key personnel; (c) intellectual property including the ability of the\nCompany to protect its intellectual property and dependence on its strategic\npartners; and (d) capital structure, including its lack of dividends on its\ncommon shares, volatility of the market price of its common shares and public\ncompany costs. Further information about these and other risks and\nuncertainties can be found in the disclosure documents filed by the Company\nwith applicable securities regulatory authorities, available\nat www.sedarplus.ca. The Company cautions that the foregoing list of factors\nthat may affect future results is not exhaustive.\n\nA photo accompanying this announcement is available at\nhttps://www.globenewswire.com/NewsRoom/AttachmentNg/30f95b0d-a64d-4c49-9c56-daf2a8e2d906\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/a2ad1d52-1d5a-425c-93de-45cc52c3784b)\nU.S. FDA 510(k) cleared and Health Canada approved revyve Antimicrobial Wound\nGel and revyve Antimicrobial Wound Gel Spray \n(https://www.globenewswire.com/NewsRoom/AttachmentNg/30f95b0d-a64d-4c49-9c56-daf2a8e2d906/en)\nU.S. FDA 510(k) cleared and Health Canada approved revyve Antimicrobial Wound\nGel and revyve Antimicrobial Wound Gel Spray\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-09-09T11:05:00.155517775Z","server_sent_at_ms":1788951900155},"received_at":"2026-09-09T11:05:00.238Z","source_url":null},"analysis":{"id":"127735","press_release_id":"138896","analysis_json":{"industry":{"label":"Health Care Equipment","sector":"Health Care"},"redFlags":["Interim CEO still in place — permanent leadership unresolved","Forward-looking disclosure cites lack of significant revenues to date and reliance on equity and other financing"],"eventType":"other","narrative":"Kane Biotech (TSX-V: KNE) will host a virtual Commercial Update webcast on Wednesday, September 16, 2026, at 11:00 a.m. Eastern Time, with a replay available on its website.\n\nThe one-hour session will feature Interim CEO Dr. Robert Huizinga, Board Chair Philip Renaud, and wound-care surgeon Dr. John C. Lantis, focusing on the strategy to convert the FDA 510(k)-cleared revyve wound-care portfolio into sustained clinical adoption and recurring revenue.\n\nThis release is a scheduling notice with no new financial, regulatory, or clinical data; any substantive signal will come from the webcast itself, so agents should treat it as a calendar item rather than news.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine webcast scheduling notice — set a reminder for the September 16 event, where revyve commercial-traction details may actually land."},"keyFigures":{"customDimensions":{"webcast_date":"2026-09-16","webcast_time":"11:00 a.m. Eastern Time","webcast_duration":"approximately 60 minutes including Q&A"}},"quotedText":"Product clearance and scientific evidence are essential, but they are not the same as commercial success","namedEntities":{"people":[{"name":"Philip Renaud","role":"Chair of the Board of Directors"},{"name":"Dr. Robert Huizinga","role":"Interim Chief Executive Officer"},{"name":"Dr. John C. Lantis","role":"Site Chief of Surgery, Mount Sinai West Hospital; Professor of Surgery, Icahn School of Medicine at Mount Sinai"},{"name":"Ray Dupuis","role":"Chief Financial Officer"}],"products":["revyve Antimicrobial Wound Gel","revyve Antimicrobial Wound Gel Spray","revyve Antimicrobial Skin and Wound Cleanser"],"companies":[{"name":"Kane Biotech Inc.","ticker":"KNE","relationship":"filer"},{"name":"Mount Sinai West Hospital","relationship":"mentioned (presenter affiliation)"},{"name":"U.S. Food and Drug Administration","relationship":"regulator (510(k) clearance)"},{"name":"Health Canada","relationship":"regulator (product approval)"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"This is a scheduling announcement for an upcoming investor webcast; it contains no new financial results, regulatory decisions, or clinical data. The only substance is a preview of what will be discussed on September 16."},"tickerRelevance":{"others":[],"primary":"KNE"},"globalImportance":10,"audienceRelevance":8,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"micro-cap (TSX-V)","eventGravity":"webcast-scheduling-notice","issuerAuthored":true,"newInformation":"none","retailFavoriteBoost":false}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Kane Biotech (TSX-V: KNE) will host a virtual Commercial Update webcast on Wednesday, September 16, 2026, at 11:00 a.m. Eastern Time, with a replay available on its website.\n\nThe one-hour session will feature Interim CEO Dr. Robert Huizinga, Board Chair Philip Renaud, and wound-care surgeon Dr. John C. Lantis, focusing on the strategy to convert the FDA 510(k)-cleared revyve wound-care portfolio into sustained clinical adoption and recurring revenue.\n\nThis release is a scheduling notice with no new financial, regulatory, or clinical data; any substantive signal will come from the webcast itself, so agents should treat it as a calendar item rather than news.","key_figures":{"customDimensions":{"webcast_date":"2026-09-16","webcast_time":"11:00 a.m. Eastern Time","webcast_duration":"approximately 60 minutes including Q&A"}},"named_entities":{"people":[{"name":"Philip Renaud","role":"Chair of the Board of Directors"},{"name":"Dr. Robert Huizinga","role":"Interim Chief Executive Officer"},{"name":"Dr. John C. Lantis","role":"Site Chief of Surgery, Mount Sinai West Hospital; Professor of Surgery, Icahn School of Medicine at Mount Sinai"},{"name":"Ray Dupuis","role":"Chief Financial Officer"}],"products":["revyve Antimicrobial Wound Gel","revyve Antimicrobial Wound Gel Spray","revyve Antimicrobial Skin and Wound Cleanser"],"companies":[{"name":"Kane Biotech Inc.","ticker":"KNE","relationship":"filer"},{"name":"Mount Sinai West Hospital","relationship":"mentioned (presenter affiliation)"},{"name":"U.S. Food and Drug Administration","relationship":"regulator (510(k) clearance)"},{"name":"Health Canada","relationship":"regulator (product approval)"}],"dollarAmounts":[]},"model_name":"glm-5.3-flash","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-09T11:08:54.539Z","global_importance":10,"audience_relevance":8,"importance_components":{"tickerTier":"micro-cap (TSX-V)","eventGravity":"webcast-scheduling-notice","issuerAuthored":true,"newInformation":"none","retailFavoriteBoost":false}},"durationMs":34003,"modelName":"glm-5.3-flash"}}